

Mycoplasma





Important Human Mycoplasma

Mycoplasmataceae – requiring

cholesterol or other sterols as an essential grwoth factor.

a. Genus *Mycoplasma* which utilize glucose or arginine but donot split urea.


b. Genus *Ureaplasma* – which hydrolyze urea

Basic Characters of Mycoplasma

- Prokaryotic microbes
- Size of 150-250 nm
- Lack of a cell wall
- Sterol-containing cell membrane
- Fastidious growth requirements
- Fried-egg or mulberry colonies on agar




Mycoplasma are cell wall deficient microorganisms



Cross-section of **Mycoplasma** bacteria, a common cause of atypical pneumonia. This bacteria is unusual in that it lacks a cell wall

Culturing Mycoplasma

- cultured on liquid or solid medium
- Growths optimally at 35 to 37°c
- Medium of growth should be enriched with 20% horse or human serum.
- The colonies appears as fried egg appearance



Diseases Caused by Mycoplasma Organism Disease

- *M. pneumoniae* Upper respiratory tract disease, tracheobronchitis, atypical pneumonia, (chronic asthma?)
- *M. hominis* Pyleonephritis, pelvic inflammatory disease, postpartum fever
- *M. genitalium* Nongonococcal urethritis

U. urealyticum Nongonococcal urethritis, (pneumonia and chronic lung disease in premature infants?)

Morphology and Physiology


• Lack a cell wall


Insensitive to antibiotics that inhibit cell wall synthesis "Fried egg" colonies on special agar after 3-4 days


- Smallest free-living bacteria (0.2 0.8 :m) Frequently pass thru bacteriologic filters
- Contain sterols in cell membranes
- Small genome size

Require complex media and external cholesterol for growth

- Facultative anaerobes
- Except *M. pneumoniae* strict aerobe
- Grow slowly by binary fission







Pathogenesis - Mycoplasma

Adherence

- P1 pili (M. pneumoniae)
- movement of cilia ceases
- clearance mechanism stops -cough

Toxic metabolic products


peroxide and superoxide radicals
inhibition of catalase host
cell membrane damage

Immunopathogenesis

- activate macrophages
- stimulate cytokine production

superantigen (M. pneumoniae)

M. pneumoniae adhesin sequences bear significant homology to mammalian structural proteins (CD4 and Major Histocompatibility Complex type II lymphocyte proteins)



Mycoplasma pneumoniae

- Tracheobronchitis 70-80% of infections
- Atypical pneumonia ~10% of infection
 - Mild disease but long duration
 - "Primary atypical pneumonia"
- Shed in saliva several days before onset of clinical disease; re-infection is common
- Spread by aerosol route (Confined populations)
- Disease of the young (5-20 years), although all ages are at risk
- No seasonal variation
- Proportionally higher in summer
- Occurs worldwide

Transmission of Mycoplasma Infections

- The disease is world wide,
- Transmission by drop let infection of nasopharyngeal secretions.
- Spread is associated with close contact of infected person
- Important infection in Military personal.
- Even the persons recovered from infection will harbor the pathogens for 2 months or more




Clinical Manifestations

- Generalized aches and pains
- Fever (usually 102°F)
- Cough Usually non-productive
- Sore throat
- Headache/ myalgias
- Chills but not rigors
- Nasal congestion

Respiratory spread

Infection moves easily among people in close contact because it is spread primarily when infected droplets from the respiratory system circulate in the air due to coughing, spitting, or sneezing



Pneumonia leading Manifestation in Mycoplasma infections



Laboratory Diagnosis

Microscopy - difficult to stain

- help eliminate other organisms

Culture (definitive diagnosis)

- sputum (usually scant) or throat washings
- special transport medium needed
- may take 2-3 weeks

Serology

- Complement fixation
- May take 4-6 weeks, fourfold rise in titer between acute & convalescent samples
- Cold agglutinins I antigen
- 1/3 2/3 of patients
- Appear first, on-specific, presumptive diagnosis
- Molecular diagnosis -PCR-based tests

Treatment and Prevention *M. pneumoniae*

• Treatment

- Tetracycline or
 - erythromycin Newer
 - fluoroquinolones
- Can't use cell wall synthesis antibiotics

• Prevention

- Washing hands
- Avoid close contact
- No vaccine

